A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes

ABSTRACT Group A streptococcus (GAS) species are responsible for a broad spectrum of human diseases, ranging from superficial to invasive infections, and are associated with autoimmune disorders. There is no commercial vaccine against GAS. The clinical manifestations of GAS infection may be attribut...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Shuai Bi, Meiyi Xu, Ya Zhou, Xinxin Xing, Adong Shen, Beinan Wang
Formato:	article
Lenguaje:	EN
Publicado:	American Society for Microbiology 2019
Materias:	B-cell responses Th17 adaptive immunity group A streptococcus vaccines Microbiology QR1-502
Acceso en línea:	https://doaj.org/article/229a172403f948d68d03957fb4c267a1
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:229a172403f948d68d03957fb4c267a1
record_format	dspace
spelling	oai:doaj.org-article:229a172403f948d68d03957fb4c267a12021-11-15T15:54:45ZA Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes10.1128/mBio.02600-192150-7511https://doaj.org/article/229a172403f948d68d03957fb4c267a12019-12-01T00:00:00Zhttps://journals.asm.org/doi/10.1128/mBio.02600-19https://doaj.org/toc/2150-7511ABSTRACT Group A streptococcus (GAS) species are responsible for a broad spectrum of human diseases, ranging from superficial to invasive infections, and are associated with autoimmune disorders. There is no commercial vaccine against GAS. The clinical manifestations of GAS infection may be attributable to the large repertoire of virulence factors used selectively in different types of GAS disease. Here, we selected five molecules, highly conserved among GAS serotypes, and involved in different pathogenic mechanisms, as a multicomponent vaccine, 5CP. Intranasal (i.n.) immunization with 5CP protected mice against both mucosal and systemic GAS infection across serotypes; the protection lasted at least 6 months. Immunization of mice with 5CP constrained skin lesion development and accelerated lesion recovery. Flow cytometry and enzyme-linked immunosorbent assay analyses revealed that 5CP induced Th17 and antibody responses locally and systemically; however, the Th17 response induced by 5CP resolved more quickly than that to GAS when challenge bacteria were cleared, suggesting that 5CP is less likely to cause autoimmune responses. These findings support that immunization through the i.n. route targeting multiple nonredundant virulence factors can induce immunity against different types of GAS disease and represents an alternative strategy for GAS vaccine development, with favorable efficacy, coverage, duration, and safety. IMPORTANCE GAS is among the most common human pathogens and causes a wide variety of diseases, likely more than any other microorganism. The diverse clinical manifestations of GAS may be attributable to its large repertoire of virulence factors that are selectively and synergistically involved in streptococcal pathogenesis. To date, GAS vaccines have not been successful due to multiple serotypes and postinfection sequelae associated with autoimmunity. In this study, five conserved virulence factors that are involved in GAS pathogenesis were used as a combined vaccine. Intranasal immunization with this vaccine induced humoral and cellular immune responses across GAS serotypes and protected against mucosal, systemic, and skin infections. The significance of this work is to demonstrate that the efficacy of GAS vaccines can be achieved by including multiple nonredundant critical virulence factors and inducing local and systemic immunity. The strategy also provides valuable insights for vaccine development against other pathogens.Shuai BiMeiyi XuYa ZhouXinxin XingAdong ShenBeinan WangAmerican Society for MicrobiologyarticleB-cell responsesTh17adaptive immunitygroup A streptococcusvaccinesMicrobiologyQR1-502ENmBio, Vol 10, Iss 6 (2019)
institution	DOAJ
collection	DOAJ
language	EN
topic	B-cell responses Th17 adaptive immunity group A streptococcus vaccines Microbiology QR1-502
spellingShingle	B-cell responses Th17 adaptive immunity group A streptococcus vaccines Microbiology QR1-502 Shuai Bi Meiyi Xu Ya Zhou Xinxin Xing Adong Shen Beinan Wang A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes
description	ABSTRACT Group A streptococcus (GAS) species are responsible for a broad spectrum of human diseases, ranging from superficial to invasive infections, and are associated with autoimmune disorders. There is no commercial vaccine against GAS. The clinical manifestations of GAS infection may be attributable to the large repertoire of virulence factors used selectively in different types of GAS disease. Here, we selected five molecules, highly conserved among GAS serotypes, and involved in different pathogenic mechanisms, as a multicomponent vaccine, 5CP. Intranasal (i.n.) immunization with 5CP protected mice against both mucosal and systemic GAS infection across serotypes; the protection lasted at least 6 months. Immunization of mice with 5CP constrained skin lesion development and accelerated lesion recovery. Flow cytometry and enzyme-linked immunosorbent assay analyses revealed that 5CP induced Th17 and antibody responses locally and systemically; however, the Th17 response induced by 5CP resolved more quickly than that to GAS when challenge bacteria were cleared, suggesting that 5CP is less likely to cause autoimmune responses. These findings support that immunization through the i.n. route targeting multiple nonredundant virulence factors can induce immunity against different types of GAS disease and represents an alternative strategy for GAS vaccine development, with favorable efficacy, coverage, duration, and safety. IMPORTANCE GAS is among the most common human pathogens and causes a wide variety of diseases, likely more than any other microorganism. The diverse clinical manifestations of GAS may be attributable to its large repertoire of virulence factors that are selectively and synergistically involved in streptococcal pathogenesis. To date, GAS vaccines have not been successful due to multiple serotypes and postinfection sequelae associated with autoimmunity. In this study, five conserved virulence factors that are involved in GAS pathogenesis were used as a combined vaccine. Intranasal immunization with this vaccine induced humoral and cellular immune responses across GAS serotypes and protected against mucosal, systemic, and skin infections. The significance of this work is to demonstrate that the efficacy of GAS vaccines can be achieved by including multiple nonredundant critical virulence factors and inducing local and systemic immunity. The strategy also provides valuable insights for vaccine development against other pathogens.
format	article
author	Shuai Bi Meiyi Xu Ya Zhou Xinxin Xing Adong Shen Beinan Wang
author_facet	Shuai Bi Meiyi Xu Ya Zhou Xinxin Xing Adong Shen Beinan Wang
author_sort	Shuai Bi
title	A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes
title_short	A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes
title_full	A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes
title_fullStr	A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes
title_full_unstemmed	A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes
title_sort	multicomponent vaccine provides immunity against local and systemic infections by group a streptococcus across serotypes
publisher	American Society for Microbiology
publishDate	2019
url	https://doaj.org/article/229a172403f948d68d03957fb4c267a1
work_keys_str_mv	AT shuaibi amulticomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT meiyixu amulticomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT yazhou amulticomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT xinxinxing amulticomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT adongshen amulticomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT beinanwang amulticomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT shuaibi multicomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT meiyixu multicomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT yazhou multicomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT xinxinxing multicomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT adongshen multicomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes AT beinanwang multicomponentvaccineprovidesimmunityagainstlocalandsystemicinfectionsbygroupastreptococcusacrossserotypes
_version_	1718427201786871808

A Multicomponent Vaccine Provides Immunity against Local and Systemic Infections by Group A Streptococcus across Serotypes

Ejemplares similares